Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Current Assets: 2022-2025

Historic Current Assets for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $732.3 million.

  • NewAmsterdam Pharma Co N.V's Current Assets rose 67.25% to $732.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $732.3 million, marking a year-over-year increase of 67.25%. This contributed to the annual value of $863.4 million for FY2024, which is 148.97% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Current Assets stood at $732.3 million for Q3 2025, which was down 4.87% from $769.9 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Current Assets registered a high of $863.4 million during Q4 2024, and its lowest value of $389,264 during Q2 2023.
  • Its 3-year average for Current Assets is $544.6 million, with a median of $487.8 million in 2024.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Current Assets decreased by 27.45% in 2023 and then spiked by 114,308.73% in 2024.
  • Over the past 4 years, NewAmsterdam Pharma Co N.V's Current Assets (Quarterly) stood at $478.0 million in 2022, then fell by 27.45% to $346.8 million in 2023, then spiked by 148.97% to $863.4 million in 2024, then spiked by 67.25% to $732.3 million in 2025.
  • Its Current Assets was $732.3 million in Q3 2025, compared to $769.9 million in Q2 2025 and $817.3 million in Q1 2025.